Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyElacestrant vs. Standard Endocrine Therapy for ER+, HER2– Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

This randomized, open-label, phase III trial compared elacestrant, a novel, oral selective ER degrader, vs. standard of care endocrine monotherapy in patients with ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a cyclin-dependent kinase 4/6 inhibitor, and ≤ 1 chemotherapy. Elacestrant showed a significant PFS improvement versus SOC both in the overall population and in patients with ESR1 mutations.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form